These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 25158302)
1. TLR4 signaling: a potential therapeutic target in ischemic coronary artery disease. Jia SJ; Niu PP; Cong JZ; Zhang BK; Zhao M Int Immunopharmacol; 2014 Nov; 23(1):54-9. PubMed ID: 25158302 [TBL] [Abstract][Full Text] [Related]
2. Expression of miR-146a/b is associated with the Toll-like receptor 4 signal in coronary artery disease: effect of renin-angiotensin system blockade and statins on miRNA-146a/b and Toll-like receptor 4 levels. Takahashi Y; Satoh M; Minami Y; Tabuchi T; Itoh T; Nakamura M Clin Sci (Lond); 2010 Jul; 119(9):395-405. PubMed ID: 20524934 [TBL] [Abstract][Full Text] [Related]
3. Circulating Toll-like receptor 4-responsive microRNA panel in patients with coronary artery disease: results from prospective and randomized study of treatment with renin-angiotensin system blockade. Satoh M; Takahashi Y; Tabuchi T; Tamada M; Takahashi K; Itoh T; Morino Y; Nakamura M Clin Sci (Lond); 2015 Apr; 128(8):483-91. PubMed ID: 25385173 [TBL] [Abstract][Full Text] [Related]
4. Role of vascular inflammation in coronary artery disease: potential of anti-inflammatory drugs in the prevention of atherothrombosis. Inflammation and anti-inflammatory drugs in coronary artery disease. Moreira DM; da Silva RL; Vieira JL; Fattah T; Lueneberg ME; Gottschall CA Am J Cardiovasc Drugs; 2015 Feb; 15(1):1-11. PubMed ID: 25369900 [TBL] [Abstract][Full Text] [Related]
5. Expression of let-7i is associated with Toll-like receptor 4 signal in coronary artery disease: effect of statins on let-7i and Toll-like receptor 4 signal. Satoh M; Tabuchi T; Minami Y; Takahashi Y; Itoh T; Nakamura M Immunobiology; 2012 May; 217(5):533-9. PubMed ID: 21899916 [TBL] [Abstract][Full Text] [Related]
6. Toward immunomodulatory and anti-inflammatory properties of statins. Arnaud C; Braunersreuther V; Mach F Trends Cardiovasc Med; 2005 Aug; 15(6):202-6. PubMed ID: 16182129 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of innate immunity with Toll-like receptor 4 (TLR4) antagonists. Peri F; Piazza M Biotechnol Adv; 2012; 30(1):251-60. PubMed ID: 21664961 [TBL] [Abstract][Full Text] [Related]
8. STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease. Sikorski K; Czerwoniec A; Bujnicki JM; Wesoly J; Bluyssen HA Cytokine Growth Factor Rev; 2011 Aug; 22(4):211-9. PubMed ID: 21752694 [TBL] [Abstract][Full Text] [Related]
9. Cellular and molecular mechanisms of statins: an update on pleiotropic effects. Satoh M; Takahashi Y; Tabuchi T; Minami Y; Tamada M; Takahashi K; Itoh T; Morino Y; Nakamura M Clin Sci (Lond); 2015 Jul; 129(2):93-105. PubMed ID: 25927679 [TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor 2 and 4 stimulation elicits an enhanced inflammatory response in human obese patients with atherosclerosis. Scholtes VP; Versteeg D; de Vries JP; Hoefer IE; Schoneveld AH; Stella PR; Doevendans PA; van Keulen KJ; de Kleijn DP; Moll FL; Pasterkamp G Clin Sci (Lond); 2011 Sep; 121(5):205-14. PubMed ID: 21446916 [TBL] [Abstract][Full Text] [Related]
11. Role of Toll like receptor signaling pathway in ischemic coronary artery disease. Satoh M; Ishikawa Y; Minami Y; Takahashi Y; Nakamura M Front Biosci; 2008 May; 13():6708-15. PubMed ID: 18508689 [TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor signaling pathways in cardiovascular diseases: challenges and opportunities. Moghimpour Bijani F; Vallejo JG; Rezaei N Int Rev Immunol; 2012 Oct; 31(5):379-95. PubMed ID: 23083347 [TBL] [Abstract][Full Text] [Related]
13. Drug Targeting Based on a New Concept-Targeting Against TLR4 as an Example. Maru Y; Tomita T; Deguchi A; Ieguchi K; Takita M; Tsukahara F; Takemura K; Kitao A; Gusovsky F Endocr Metab Immune Disord Drug Targets; 2015; 15(2):83-7. PubMed ID: 26004773 [TBL] [Abstract][Full Text] [Related]
14. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Boekholdt SM; Agema WR; Peters RJ; Zwinderman AH; van der Wall EE; Reitsma PH; Kastelein JJ; Jukema JW; Circulation; 2003 May; 107(19):2416-21. PubMed ID: 12742999 [TBL] [Abstract][Full Text] [Related]
15. Inflammatory unbalance of TLR3 and TLR4 in PCI patients with or without type 2 diabetes mellitus. Shao L; Zhang P; Zhang Y; Ma A Immunol Lett; 2014 Sep; 161(1):81-8. PubMed ID: 24845156 [TBL] [Abstract][Full Text] [Related]